The USPTO has extended the term of Puma Biotechnology's patent on NERLYNX (neratinib) for an additional 5 years, through Dec. 29, 2030.
News
- Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib ...
- Yoga improves quality of life in men with new diagnosis of prostate cancer - EurekAlert!
University of Texas Health Science Center at San Antonio ... dentistry, health professions and graduate biomedical sciences have graduated 39,700 ...
- New study offers key to further protection against COVID-19
In the largest study of its kind, Texas Biomedical Research Institute in San Antonio tracked waning antibodies against COVID-19 by gender, ...
- COVID cases decline in San Antonio, officials recommend to continue following safety guidelines
San Antonio's coronavirus risk level is currently low as the city sees a steady decline in positive COVID-19 cases, according to weekly ...
- Baylor College of Medicine, Texas Children's Hospital announce licensing agreement for ...
... which will leverage its biotechnology experience by further developing and commercializing the vaccine candidate, which is produced using a ...